JP2023030106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023030106A5 JP2023030106A5 JP2022205330A JP2022205330A JP2023030106A5 JP 2023030106 A5 JP2023030106 A5 JP 2023030106A5 JP 2022205330 A JP2022205330 A JP 2022205330A JP 2022205330 A JP2022205330 A JP 2022205330A JP 2023030106 A5 JP2023030106 A5 JP 2023030106A5
- Authority
- JP
- Japan
- Prior art keywords
- curcumin
- hours
- weeks
- curcuminoid
- lysophosphatidylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655095P | 2018-04-09 | 2018-04-09 | |
| US62/655,095 | 2018-04-09 | ||
| PCT/US2019/024495 WO2019199469A1 (en) | 2018-04-09 | 2019-03-28 | Dosing regimens for treatment of proliferative disorders |
| JP2020555189A JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555189A Division JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023030106A JP2023030106A (ja) | 2023-03-07 |
| JP2023030106A5 true JP2023030106A5 (cg-RX-API-DMAC7.html) | 2023-04-10 |
Family
ID=68164516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555189A Active JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
| JP2022205330A Pending JP2023030106A (ja) | 2018-04-09 | 2022-12-22 | 増殖性障害の治療のための投薬レジメン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555189A Active JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11813356B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773529B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7241426B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240027843A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112272555A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019250832B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3096591C (cg-RX-API-DMAC7.html) |
| ES (1) | ES3061642T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020010651A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI737974B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019199469A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
| EP4675742A4 (en) | 2023-02-28 | 2026-06-17 | Panasonic Ip Man Co Ltd | SECONDARY BATTERY WITH NON-AQUEAL ELECTROLYTE |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1299085B1 (en) * | 2000-06-30 | 2005-11-16 | Inex Pharmaceuticals Corp. | Improved liposomal camptothecins and uses thereof |
| US8563525B2 (en) * | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US7968115B2 (en) * | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
| US8784881B2 (en) * | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
| CN1973834A (zh) * | 2006-12-15 | 2007-06-06 | 中国科学院长春应用化学研究所 | 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用 |
| UA99914C2 (ru) | 2007-05-15 | 2012-10-25 | Оцука Фармас'Ютікел Ко., Лтд. | Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности |
| CN101766619B (zh) * | 2008-12-30 | 2011-08-24 | 武汉大学 | 一种治疗恶性肿瘤的药物组合物及应用 |
| EP2501372A4 (en) | 2009-11-19 | 2013-04-10 | Signpath Pharma Inc | INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER |
| HK1208907A1 (en) | 2012-06-14 | 2016-03-18 | Signpath Pharma Inc. | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin |
| WO2014036534A1 (en) | 2012-08-31 | 2014-03-06 | University Of North Texas Health Science Center | Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy |
| WO2015077640A1 (en) | 2013-11-22 | 2015-05-28 | Signpath Pharma, Inc. | Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders |
| JP6895252B2 (ja) * | 2013-12-18 | 2021-06-30 | サインパス ファルマ, インク.Signpath Pharma, Inc. | 心筋ikrチャネルの薬剤誘発性阻害のリポソームによる軽減 |
| KR101755245B1 (ko) | 2015-08-12 | 2017-07-07 | 연세대학교 원주산학협력단 | 단량체 염을 이용한 폴리이미드 복합체 제조방법 |
| CA2940470C (en) | 2015-09-18 | 2019-08-20 | Signpath Pharma Inc. | Treatment for glioblastoma |
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
-
2019
- 2019-03-27 TW TW108110582A patent/TWI737974B/zh active
- 2019-03-28 JP JP2020555189A patent/JP7241426B2/ja active Active
- 2019-03-28 EP EP19785177.7A patent/EP3773529B1/en active Active
- 2019-03-28 MX MX2020010651A patent/MX2020010651A/es unknown
- 2019-03-28 AU AU2019250832A patent/AU2019250832B2/en active Active
- 2019-03-28 US US17/045,431 patent/US11813356B2/en active Active
- 2019-03-28 KR KR1020247004962A patent/KR20240027843A/ko not_active Withdrawn
- 2019-03-28 KR KR1020207031775A patent/KR102637598B1/ko active Active
- 2019-03-28 CN CN201980037784.6A patent/CN112272555A/zh active Pending
- 2019-03-28 WO PCT/US2019/024495 patent/WO2019199469A1/en not_active Ceased
- 2019-03-28 CA CA3096591A patent/CA3096591C/en active Active
- 2019-03-28 ES ES19785177T patent/ES3061642T3/es active Active
-
2022
- 2022-12-22 JP JP2022205330A patent/JP2023030106A/ja active Pending
-
2023
- 2023-10-04 US US18/480,678 patent/US12551436B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Green et al. | Pegylated liposomal doxorubicin in ovarian cancer | |
| RU2640485C2 (ru) | Комбинированное лечение рака | |
| CN106456626B (zh) | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 | |
| US20070265213A1 (en) | Use of Docetaxel/Doxorubicin/Cyclophosphamide in Adjuvant Therapy | |
| BRPI0707059A2 (pt) | método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação | |
| Alexopoulos et al. | Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer | |
| Tolba et al. | Cardiotoxicity of cancer therapy | |
| IL319266A (en) | RAD1901 for use in cancer treatment | |
| Mrozek et al. | Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients | |
| AU2019266150A1 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| Numico et al. | Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial | |
| JP2026001134A (ja) | ミトキサントロン塩酸塩リポソームの応用 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JP2025511402A5 (cg-RX-API-DMAC7.html) | ||
| JP2025511401A5 (cg-RX-API-DMAC7.html) | ||
| US20110159080A1 (en) | Composition comprising liposome-entrapped doxorubicin and methods of administration | |
| WO2000069467A1 (en) | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound | |
| WO2019023873A1 (zh) | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 | |
| Jones et al. | Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin | |
| JP2025511403A5 (cg-RX-API-DMAC7.html) | ||
| WO2023284597A1 (zh) | 用于治疗癌症的组合疗法 | |
| EP3442534A1 (en) | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer | |
| Comis | Oral etoposide in oncology: an evolving role | |
| Batist | Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancer | |
| WO2023283380A1 (en) | Nanoparticles for cancer treatment |